{"id":"W4281396346","doi":"10.2217/fon-2021-1629","title":"Targeting <i>FGFR3</i> Alterations with Adjuvant Infigratinib in Invasive Urothelial Carcinoma: the Phase III PROOF 302 Trial","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Helsinn","keywords":"Medicine; Placebo; Clinical endpoint; Tolerability; Metastatic Urothelial Carcinoma; Internal medicine; Oncology; Adjuvant; Bladder cancer; Cisplatin; Urothelial cancer; Urology; Randomized controlled trial; Adverse effect; Urothelial carcinoma; Cancer; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002723247,0.0002135315,0.0004727678,0.0001052381,0.0004020238,0.00001543135,0.0001567631,0.00008825609,0.0008630967],"category_scores_gemma":[0.00004671785,0.0001329421,0.00008387653,0.0003583565,0.00009370391,0.00006202995,0.00008184727,0.0006380168,0.000008289813],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003802401,"about_ca_system_score_gemma":0.001845928,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002879839,"about_ca_topic_score_gemma":0.001521402,"domain_scores_codex":[0.9982532,0.0003424708,0.0003959395,0.0003560578,0.0003065676,0.0003457995],"domain_scores_gemma":[0.999232,0.0001509612,0.0001682917,0.0002809947,0.00007086401,0.00009687667],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.6362478,0.01950552,0.0260243,0.0002229313,0.001193226,0.006531858,0.06946618,0.001106074,0.02376309,0.003250044,0.1590147,0.05367439],"study_design_scores_gemma":[0.4702234,0.03673089,0.001605667,0.0000323981,0.0005222005,0.0006462404,0.009059312,0.0001712437,0.002795954,0.0001370442,0.4776783,0.000397342],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9618933,0.001218694,0.00007294672,0.01790565,0.002055048,0.005736943,0.0002356693,0.00006334408,0.01081839],"genre_scores_gemma":[0.9900642,0.0000266739,0.0002550586,0.003969079,0.00252865,0.002253369,0.0002315902,0.00003387621,0.0006375278],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3186637,"threshold_uncertainty_score":0.9450304,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01913689018658343,"score_gpt":0.3077494896688529,"score_spread":0.2886125994822695,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}